Skip to main content
. 2016 Jun 23;9:3763–3770. doi: 10.2147/OTT.S102909

Figure 4.

Figure 4

TNM stage-wise survivability.

Notes: (A) There was a statistically significant survival difference between immunotherapy and control group in stage III gastric cancer patients (median survival in immunotherapy, 36.63 months; in control, 24.47 months; P=0.034). (B) There was no significant survival difference between immunotherapy and control groups in stage IV gastric cancer patients (mean survival time in immunotherapy, 20.30 months; in control, 11.60 months; P=0.350).

Abbreviation: TNM, tumor-node-metastasis.